中新网广州1月3日电(王华 晓雷)记者今日从由中华医学研究会肝病委员会在穗主办的“全国规范乙肝防治高峰论坛”上获悉，由于乙肝治疗的不规范，致中国慢性乙肝停药后复发的比例超过50%，人数每年超100万。中华医学研究会肝病委员会今天正式启用首条免费预防乙肝耐药、复发康复热线。

Beijing on January 3, in guangzhou(Wang hua XiaoLei)Reporter from today by the iom committee sponsored by a spike in liver disease"National standard peak hepatitis b prevention and control of BBS"We have learned,Due to the treatment of hepatitis b is not standard,To China's chronic hepatitis b recurrence after discontinuation of more than 50%,Number of more than 1 million each year.The iom preventing hepatitis b liver disease committee was officially opened today first free drug resistance/Recurrence of rehabilitation hotline.

　　专家介绍，在乙肝治疗方面，患者用药吃吃停停、不规范停药现象普遍存在，此外，因感觉不到明显症状、经济原因等而停药的人不在少数，使乙肝复发现状更加严峻。

Expert introduction,In hepatitis b treatment,Patients with engine medicine to eat/Non-standard withdrawal phenomenon exists,In addition,Because feel obvious symptoms/Economic reasons, such as the withdrawal of the people is not a few,Make the situation more severe hepatitis b recurrence.

　　中华医学会感染病分会副主任成军教授指出，乙肝的抗病毒治疗通常需要2-3年时间，患者每天一片药，保证不漏服其实很难。他说，“与初治患者相比，乙肝复发患者再治疗复杂性增加。有些已经产生耐药或耐药风险较高，再治疗时需要医生根据以往病史给出个体化方案。建议正在进行口服抗病毒治疗的乙肝患者应坚持长期、规范治疗，不要轻易停药。”

The Chinese medical association infection branch, deputy director of the professor points out that setting up,Hepatitis b antiviral treatment usually takes 2-3 years,Patients with a pill every day,To ensure no missing actually is difficult.He said,"Compared with early cure patients,Increased complexity and treatment in patients with recurrent hepatitis b.Some have produce drug resistance or higher risk resistance,And treatment need a doctor based on past history individualized programs are presented.Suggestions on oral antiviral treatment of hepatitis b patients should be insisted on for a long time/Standardized treatment,Don't stop."

　　据徐成军介绍， 目前对乙肝复发主要有两大治疗策略：选择两种没有交叉耐药位点的口服抗病毒药进行联合治疗；换用与以往用药没有交叉耐药位点的口服抗病毒药物。

Introduce according to XuChengJun, At present there are mainly two treatment strategies to hepatitis b recurrence:Choose two no cross resistance loci of oral antiviral drug combination therapy;Change with previous drug no cross resistance loci of oral antiviral drugs.

　　中华医学研究会肝病委员会杨君教授则认为，当前，临床上可供选择的慢性乙肝抗病毒药物很多，但如果初始治疗选择不当，产生病毒耐药而导致换药，而后再耐药，再换药或加药……如此循环，慢性乙肝患者可能面临多药耐药，在治疗之路上越走越窄，直至最后无药可用的地步。因此，如有可能，初始治疗应选择抗病毒活性强、低耐药的药物，这已经是当今国际医学界对慢性乙肝治疗的共识。

The iom committee converter professors that liver disease,The current,Many clinical selection of chronic hepatitis b antiviral drugs,But if the initial treatment options,Produce virus resistant to treatment,Then the resistance,To post or dosing...so,Chronic hepatitis b patients may face more than medicine drug resistance,In the treatment of the way more walk more narrow,Until finally no medicine can be used.so,If possible,Initial treatment should choose strong antiviral activity/Low resistance to drugs,This is the consensus of the international medical treatment for chronic hepatitis b.

　　杨教授提醒乙肝复发患者，千万不能轻信各种“偏方”、“秘方”以及广告药物，治疗方案及实施过程均在正规医院、正规医师指导下进行。中华医学研究会乙肝委员会特别开通预防乙肝耐药、复发康复热线4009991700，为乙肝患者提供规范治疗指引。

Professor Yang remind patients with hepatitis b recurrence,Never believe all"Folk prescription"/"Secret recipe"Advertising agents and,In normal hospital treatment plan and implementation process/Regular under guidance of physician.The iom committee of hepatitis b special opening to prevent hepatitis b resistance/Recurrence of rehabilitation hotline 4009991700,For hepatitis b patients to provide standardized treatment guidelines.